Share innovation

UroLift®: prostatic urethral lift

By Justin Hall, Neotract Added 24th October, 2016

About

TIER 1 APPROVED

UroLift® is a proven minimally invasive day-case treatment for men with an enlarged prostate, BPH (Benign Prostatic Hyperplasia), secondary to LUTS (lower urinary tract symptoms).

Men with BPH, a benign condition where the enlarged prostate presses on or blocks the urethra causing urinary issues, or LUTS, can benefit from UroLift®: 30 minute procedure under local anaesthetic involving adjustable, permanent implants holding excess prostatic tissue away from narrowing or blocking the urethra.

Patients return home after a few hours without a catheter, and rapidily return to daily living. Unlike current surgical options, UroLift® does not cause tissue injury and avoids complications associated with TURP (transurethral resection of the prostate) or laser.

Recommended by NICE (MTG26) as a cost effective alternative to TURP or laser:

  • Improved bed capacity – no overnight stay (three bed day average for TURP)
  • Improved theatre capacity - 30-minute day-case procedure (80 minutes under a general anaesthetic with TURP)
  • Reduced outpatient follow-up
  • No catheterisation – reduced risk of CAUTI
  • Easy rapidly deployable technology UroLift® does not rely on capital purchase, infrastructure or staff changes

UroLift® is part of NHS England's new Innovation and Technology Tariff, further details are also available on AHSN_Atlas_of_ Solutions_in_Healthcare

Related Innovations